信迪利单抗联合吉西他滨和顺铂对晚期肺鳞癌患者肿瘤标志物及免疫功能的影响  

Effect of Sintilima Combined with Gemcitabine and Cisplatin on Tumor Markers and Immune Function in Patients with Advanced Pulmonary Squamous Cell Carcinoma

作　　者：高莉莉[1] 夏玲玲 朱静 GAO Lili;XIA Lingling;ZHU Jing(Department of Oncology,Funing County People's Hospital,Funing 224400,Jiangsu,China)

机构地区：[1]阜宁县人民医院肿瘤科,江苏阜宁224400

出　　处：《系统医学》2025年第2期167-170,共4页Systems Medicine

摘　　要：目的探讨信迪利单抗联合吉西他滨及顺铂对晚期肺鳞癌患者肿瘤标志物、免疫功能的影响。方法非随机选取2020年10月—2023年10月阜宁县人民医院收治的82例晚期肺鳞癌患者作为研究对象,按治疗方法不同分为两组,各41例。观察组采用信迪利单抗联合吉西他滨和顺铂治疗,参照组采用吉西他滨和顺铂治疗。比较两组临床治疗效果、肿瘤标志物与免疫功能。结果治疗3个周期后,观察组客观缓解率、疾病控制率均高于参照组[60.98%(25/41)vs36.59%(15/41)、95.12%(39/41)vs80.49%(33/41)],差异有统计学意义(χ^(2)=4.881、4.100,P均<0.05)。治疗3个周期后,观察组的癌胚抗原、鳞状细胞癌抗原及糖类抗原125表达水平均低于参照组,观察组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)高于参照组,CD8^(+)低于参照组,差异有统计学意义(P均<0.05)。结论信迪利单抗联合吉西他滨及顺铂能有效控制晚期肺鳞癌患者病情进展,降低肿瘤标志物表达水平,并改善机体免疫功能,具有应用价值。Objective To investigate the effect of Sintilima combined with gemcitabine and cisplatin on tumor markers and immune function in patients with advanced pulmonary squamous cell carcinoma.Methods A total of eighty-two patients with advanced pulmonary squamous cell carcinoma admitted to Funing County People's Hospital from October 2020 to October 2023 were non-randomly selected as the study subjects.They were divided into two groups according to different treatment methods,with forty-one cases in each group.The observation group was treated with sintilima combined with gemcitabine and cisplatin,and the reference group was treated with gemcitabine and cisplatin.The clinical therapeutic effect,tumor markers and immune function were compared between the two groups.Results After 3 cycles of treatment,the objective remission rate and disease control rate of the observation group were higher than those of the reference group[60.98%(25/41)vs 36.59%(15/41),95.12%(39/41)vs 80.49%(33/41)],the differences were statistically significant(χ^(2)=4.881,4.100,both P<0.05)。After 3 cycles of treatment,the expression levels of carcinoembryonic antigen,squamous cell carcinoma antigen and carbohydrate antigen 125 in the observation group were lower than those in the reference group.The CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)in the observation group were higher than those in the reference group,and the CD8^(+)was lower than that in the reference group,and the differences were statistically significant(all P<0.05).Conclusion Sintilima combined with gemcitabine and cisplatin can effectively control the progression of patients with advanced pulmonary squamous cell carcinoma,reduce the expression level of tumor markers,and improve the immune function of the body,which has application value.

关 键 词：信迪利单抗 免疫功能 肿瘤标志物 晚期肺鳞癌 

分 类 号：R734[医药卫生—肿瘤]